David Thaler - Insights from other device trials; what can we learn from PFO trials?
About this lecture
There are many things to be learned from PFO trails for stroke prevention in other stroke prevention trials, such as the LAA occlusion trials.
David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!